We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+25.17%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$14.8B
AUM Growth
+$1.58B
Cap. Flow
-$1.22B
Cap. Flow %
-8.22%
Top 10 Hldgs %
44.34%
Holding
132
New
32
Increased
38
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$317M
2
CRM icon
Salesforce
CRM
+$270M
3
TMO icon
Thermo Fisher Scientific
TMO
+$259M
4
MDCO
Medicines Co
MDCO
+$221M
5
PPLI
People Inc
PPLI
+$137M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.55B
2
BRMK
Broadmark Realty Capital Inc. Common Stock
BRMK
+$754M
3
AABA
Altaba Inc
AABA
+$666M
4
BABA icon
Alibaba
BABA
+$196M
5
CTXS
Citrix Systems Inc
CTXS
+$183M

Sector Composition

Rank Sector Weight
1 Healthcare 46.6%
2 Communication Services 12.82%
3 Technology 9.97%
4 Industrials 5.05%
5 Financials 3.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
101
Arrowhead Research
ARWR
$12.3B
$6.34M 0.04%
100,000
-550,000
-85% -$27.3M
PHAS
102
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$6.11M 0.04%
1,000,000
+192,072
+24% +$791K
OYST
103
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$5.64M 0.04%
+230,800
New +$4.05M
ATRA icon
104
Atara Biotherapeutics
ATRA
$97.4M
$5.51M 0.04%
+13,388
New +$4.62M
XRX icon
105
Xerox
XRX
$381M
$4.79M 0.03%
+130,000
New +$4.55M
OPK icon
106
Opko Health
OPK
$1.1B
$3.67M 0.02%
+2,500,000
New +$4.19M
BRMK.WS
107
DELISTED
Broadmark Realty Capital Inc. Warrants, each exercisable for one fourth (1/4th) share of Common Stock at an exercise price of $2.875 per quarter share
BRMK.WS
$2.73M 0.02%
+7,174,613
New +$2.19M
LRMR icon
108
Larimar Therapeutics
LRMR
$434M
$2.01M 0.01%
150,697
– –
APTX
109
DELISTED
Aptinyx Inc. Common Stock
APTX
$1.4M 0.01%
408,549
-265,592
-39% -$915K
CYCN icon
110
Cyclerion Therapeutics
CYCN
$18.2M
$952K 0.01%
17,500
-1,331
-7% -$124K
ACAD icon
111
Acadia Pharmaceuticals
ACAD
$5.08B
– –
-350,000
Closed -$12.6M
AZN icon
112
AstraZeneca
AZN
$257B
– –
-1,187,893
Closed -$106M
BKNG icon
113
Booking.com
BKNG
$158B
– –
-778,475
Closed -$61.1M
COHR icon
114
Coherent
COHR
$56.7B
– –
-47,687
Closed -$1.68M
NXPI icon
115
NXP Semiconductors
NXPI
$56.9B
– –
-325,000
Closed -$35.5M
SE icon
116
Sea Limited
SE
$72B
– –
-3,375,000
Closed -$104M
UBER icon
117
PUT
Uber
UBER
$161B
– –
-1,102,500
Closed -$33.6M
CTXS
118
DELISTED
Citrix Systems Inc
CTXS
– –
-1,900,323
Closed -$183M
PFNX
119
DELISTED
Pfenex Inc.
PFNX
– –
-600,000
Closed -$5.06M
GWR
120
DELISTED
Genesee & Wyoming Inc.
GWR
– –
-782,673
Closed -$86.5M
PVTL
121
DELISTED
Pivotal Software, Inc.
PVTL
– –
-1,430,000
Closed -$21.3M
ONCE
122
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-220,000
Closed -$21.3M
BPL
123
DELISTED
Buckeye Partners, L.P.
BPL
– –
-3,900,000
Closed -$160M
ALDR
124
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-4,165,000
Closed -$78.6M
AABA
125
DELISTED
Altaba Inc
AABA
– –
-34,189,499
Closed -$666M
2 3 4
5
6

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2019 Portfolio in Review

As of Q4 2019, Thomas Steyer held 132 positions worth $14.8B, up 12% from $13.2B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Thomas Steyer withdrew a net $1.22B in Q4 2019, closing 16 positions and reducing 29 holdings. Its most notable exit was Celgene Corp, an estimated $1.55B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 45% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in Salesforce worth $281M.

  • Thomas Steyer's largest Q4 2019 buy was Salesforce: 1,724,880 shares worth $281M.
  • Thomas Steyer added most to Allergan plc in Q4 2019, an estimated $317M increase.
  • Thomas Steyer's biggest Q4 2019 reduction was Broadmark Realty Capital Inc. Common Stock, cutting an estimated $754M.
  • Thomas Steyer fully exited Celgene Corp in Q4 2019, selling an estimated $1.55B.
  • Thomas Steyer's ten largest holdings make up 44% of its $14.8B portfolio in Q4 2019.
  • Thomas Steyer opened 32 new positions and closed 16 in Q4 2019.
  • Thomas Steyer's portfolio value rose 12% quarter-over-quarter to $14.8B.

Based on Farallon Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.